NCT06743165

Brief Summary

The investigators hypothesize that Dynamic Neuromuscular Stabilization training, a next-generation exercise approach, and transabdominal ultrasound-guided pelvic floor muscle training (PFMT) will be more effective than PFMT guided solely by transabdominal ultrasound in reducing post-void residual volume, improving voiding disorder symptoms, and enhancing pelvic floor muscle relaxation in children with dysfunctional voiding.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
1mo left

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Feb 2025Jun 2026

First Submitted

Initial submission to the registry

December 16, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 19, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Expected
Last Updated

February 6, 2026

Status Verified

February 1, 2026

Enrollment Period

1 year

First QC Date

December 16, 2024

Last Update Submit

February 4, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in the amount of post-void residue

    After EMG-Uroflowmetry test: Post-void residual measurement will be made by transabdominal ultrasound 5 minutes after voiding. In repeated measurements, the amount of urine remaining in the bladder of 20 ml or more will be considered pathological.

    From enrollment to the end of treatment at 8 weeks

  • Change in EMG-Uroflowmetry measurements-peak flow rate

    EMG-Uroflowmetry test procedure: Before the test, the device will be calibrated and the scale of the interpretation sheet will be set to 1:1 for flow rate (ml/sec) and time (sec). The test will be performed in a quiet and private room and the patient will be asked to drink as much fluid as the expected bladder capacity ((age in years+1)x30) 1 hour before the test. During the test, the EMG activity of the pelvic floor muscles will also be evaluated. Voided volume (ml), peak flow rate (Q max, ml/sec) and uroflow curve interpretation will also be used. Those with decreased flow rate and stacco/interminant flow pattern will be considered pathological.

    From enrollment to the end of treatment at 8 weeks

  • Change in EMG-Uroflowmetry measurements-Pelvic Floor EMG activity

    EMG-Uroflowmetry test procedure: Before the test, the device will be calibrated and the scale of the interpretation sheet will be set to 1:1 for flow rate (ml/sec) and time (sec). The test will be performed in a quiet and private room and the patient will be asked to drink as much fluid as the expected bladder capacity ((age in years+1)x30) 1 hour before the test. During the test, the EMG activity of the pelvic floor muscles will also be evaluated. Recorded as (µV).

    From enrollment to the end of treatment at 8 weeks

Secondary Outcomes (11)

  • Change in EMG-Uroflowmetry measurements-uroflow curve

    From enrollment to the end of treatment at 8 week

  • Change in EMG-Uroflowmetry measurements - Voided volume

    From enrollment to the end of treatment at 8 weeks

  • Pelvic floor muscle assessment with ultrasound - maximum displacement (cm)

    From enrollment to the end of treatment at 8 weeks

  • Pelvic floor muscle assessment with ultrasound - coordination amplitude (cm)

    From enrollment to the end of treatment at 8 weeks

  • Pelvic floor muscle assessment with ultrasound - endurance amplitude (%)

    From enrollment to the end of treatment at 8 weeks

  • +6 more secondary outcomes

Study Arms (2)

DNS Group

EXPERIMENTAL

This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.

Behavioral: Pelvic floor muscle training with ultrasound biofeedbackBehavioral: Dynamic neuromuscular stabilization exercise

Standard exercise group

ACTIVE COMPARATOR

This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.

Behavioral: Pelvic floor muscle training with ultrasound biofeedback

Interventions

Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.

DNS GroupStandard exercise group

Dynamic neuromuscular exercises (DNS) involve the joint activation of the intrinsic muscle group of the spine, which includes the cervical flexors and extensors, diaphragm, transversus abdominis, multifidus and pelvic floor, which form the integrated spinal stabilization system. The application principles are joint centering, core stabilization - Integrated spinal stabilization system and stabilization function of the diaphragm. DNS training will be applied in three stages. Preparation for exercises, IAB regulation and application of exercises according to developmental kinesiology positions. Exercises will start with preparatory training. In preparatory training, stroking, brushing and tapping techniques will be taught and self-facilitation will be demonstrated in order to increase proprioceptive input to the lower extremity, upper extremity, trunk and pelvic region. Fascial mobilizations will be performed to the foot and hand regions.

DNS Group

Eligibility Criteria

Age6 Years - 14 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 6-14 years,
  • Diagnosed with dysfunctional urination according to uroflowmetry measurement results and clinical examination findings,
  • Children who consent to participate in the study with the consent of their mother, father or legal guardian (legal representative) will be included in the study.

You may not qualify if:

  • Children under 6 years of age,
  • Those with anatomical changes in the urinary system,
  • Those with spina bifida,
  • Those with a history of active urinary tract infection,
  • Those with a neurological disease,
  • Those with accompanying respiratory system disease,
  • Those with cognitive impairment,
  • Those with mental retardation,
  • Children whose bladder image is unclear in the pelvic floor evaluation with US,
  • Children who have previously undergone orthopedic surgery will not be included in the study.
  • PS:
  • Children who cannot comply with the application of pelvic floor muscle training,
  • Children who have missed 2 or more sessions of the treatment program will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Izmir University of Economics

Izmir, 35330, Turkey (Türkiye)

Location

Study Officials

  • Seda Yakıt Yeşilyurt, Asst. Prof.

    Izmir University of Economics

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assist. Prof.

Study Record Dates

First Submitted

December 16, 2024

First Posted

December 19, 2024

Study Start

February 1, 2025

Primary Completion

February 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

February 6, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Since no consent has been received from the institutions supporting this project to share the data with third parties, it will not be shared.

Locations